Novo Nordisk’s latest investigational weight loss treatment, CagriSema, has failed to achieve its primary endpoint of demonstrating non-inferiority when compared…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk’s investigational triple agonist, UBT251, has demonstrated a mean weight loss of 19.7% after 24 weeks in a Phase…
Read More
Novo Nordisk Sues Hims for GLP-1 Patent Infringement
In a significant escalation of the ongoing battle over the burgeoning GLP-1 weight-loss drug market, pharmaceutical giant Novo Nordisk has…
Read More
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide
Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its investigational weight loss treatment, CagriSema,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, announced a significant advancement in its weight management pipeline with…
Read More
